JAK inhibitor space hots up as Incyte pockets $50 million Phase III milestone
This article was originally published in Scrip
Executive Summary
The JAK inhibitor drug class has taken a step closer to market as Incyte/Novartis' Ruxolitinib (INCB18424) enters Phase III for the treatment of the most severe cases of polycythemia vera, triggering a $50 million milestone payment from Novartis to Incyte.